Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes

International Journal of Pharmaceutics

Volumn 493, Issue 1-2, 2015, Pages 285-294

  Shaker, Dalia S ^a,b   Shaker, Mohamed A ^a   Hanafy, Mahmoud S ^a  

^a Helwan   (Egypt)

^b Future University in Egypt   (Egypt)

Author keywords

Cancer; Cellular uptake; Cytotoxicity; MCF 7; Niosomes; Tamoxifen

Indexed keywords

NIOSOME; SORBITAN STEARATE; TAMOXIFEN CITRATE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; LIPOSOME; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER SIZE; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG UPTAKE; EHRLICH ASCITES TUMOR; FEMALE; HUMAN; HUMAN CELL; HYDRATION; IN VITRO STUDY; MOUSE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SOLID TUMOR; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; CARCINOMA, EHRLICH TUMOR; CELL SURVIVAL; DRUG EFFECTS; MCF 7 CELL LINE; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL TRANSPORT; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; LIPOSOMES; MCF-7 CELLS; MICE; TAMOXIFEN; TUMOR BURDEN;

EID: 84938876179     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.07.041     Document Type: Article

References (51)

1. A.A. Abdin, N.A. Soliman, and E.M. Saied Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in solid Ehrlich carcinoma-bearing mice Pharmacol. Rep. 66 2014 1114 1121 10.1016/j.pharep.2014.07.010
2. T. Arai, O. Benny, T. Joki, L.G. Menon, M. Machluf, T. Abe, R.S. Carroll, and P.M. Black Novel local drug delivery system using thermoreversible gel in combination with polymeric microspheres or liposomes Anticancer Res. 30 2010 1057 1064
3. P. Arunothayanun, M.S. Bernard, D.Q. Craig, I.F. Uchegbu, and A.T. Florence The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether Int. J. Pharm. 201 2000 7 14
4. K.A. Ban, and C.V. Godellas Epidemiology of breast cancer Surg. Oncol. Clin. North Am. 23 2014 409 422 10.1016/j.soc.2014.03.011
5. E.R. Bendas, H. Abdullah, M.H. El-Komy, and M.A. Kassem Hydroxychloroquine niosomes: a new trend in topical management of oral lichen planus Int. J. Pharm. 458 2013 287 295 10.1016/j.ijpharm.2013.10.042
6. M. Bragagni, N. Furlanetto, S. Furlanetto, S. Orlandini, C. Ghelardini, and P. Mura Development and characterization of functionalized niosomes for brain targeting of dynorphin-B Eur. J. Pharm. Biopharm. 87 2014 73 79 10.1016/j.ejpb.2014.01.006
7. J.S. Chawla, and M.M. Amiji Cellular uptake and concentrations of tamoxifen upon administration in poly(epsilon-caprolactone) nanoparticles AAPS PharmSci. 5 2003 E3
8. M.P. Cole, C.T. Jones, and I.D. Todd A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474 Br. J. Cancer 25 1971 270 275
9. G. Coppi, and V. Iannuccelli Alginate/chitosanmicroparticles for tamoxifen delivery to the lymphaticsystem Int. J. Pharm. 367 2009 127 132 10.1016/j.ijpharm.2008.09.040
10. D. Cosco, D. Paolino, F. Cilurzo, F. Casale, and M. Fresta Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases Int. J. Pharm. 422 2012 229 237 10.1016/j.ijpharm.2011.10.056
11. E. Dahmane, T. Mercier, B. Zanolari, S. Cruchon, N. Guignard, T. Buclin, S. Leyvraz, K. Zaman, C. Csajka, and L.A. Decosterd An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4′-hydroxylated metabolites in breast cancerpatients J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 878 2010 3402 3414 10.1016/j.jchromb.2010.10.027
12. M. Dutertre, and C.L. Smith Molecular mechanisms of selective estrogen receptor modulator (SERM) action J. Pharmacol. Exp. Ther. 295 2000 431 437
13. M.S. E.L-Ridy, A.A. Badawi, M.M. Safar, and A.M. Mohsen Niosomes as a novel pharmaceutical formulation encapsulating the hepatoprotective drug silymarin Int. J. Pharm. Pharm. Sci. 4 2012 549 559
14. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, and F. Bray Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN Int. J. Cancer 132 2012 1133 1145 10.1002/ijc.29210
15. A.S. Guinedi, N.D. Mortada, S. Mansour, and R.M. Hathout Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide Int. J. Pharm. 306 2005 71 82
16. Y.M. Hao, and K. Li Entrapment and release difference resulting from hydrogen bonding interactions in niosome Int. J. Pharm. 403 2011 245 253 10.1016/j.ijpharm.2010.10.027
17. Y. Hao, F. Zhao, N. Li, Y. Yang, and K. Li Studies on a high encapsulation of colchicine by a niosome system Int. J. Pharm. 244 2002 73 80
18. M. Hong, S. Zhu, Y. Jiang, G. Tang, and Y. Pei Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin J. Control. Release 133 2009 96 102 10.1016/j.jconrel.2008.09.005
19. A. Howell, C.K. Osborne, C. Morris, and A.E. Wakeling ICI 182,780 (Faslodex): development of a novel pure antiestrogen Cancer 89 2000 817 825
20. A.K. Jain, N.K. Swarnakar, C. Godugu, R.P. Singh, and S. Jain The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen Biomaterials 32 2011 503 515 10.1016/j.biomaterials.2010.09.037
21. V.B. Junyaprasert, P. Singhsa, J. Suksiriworapong, and D. Chantasart Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid Int. J. Pharm. 423 2012 303 311 10.1016/j.ijpharm.2011.11.032
22. B.D. Kevadiya, R.P. Thumbar, M.M. Rajput, S. Rajkumar, H. Brambhatt, G.V. Joshi, G.P. Dangi, H.M. Mody, P.K. Gadhia, and H.C. Bajaj Montmorillonite/poly-(ε-caprolactone) composites as versatile layered material: reservoirs for anticancer drug and controlled release property Eur. J. Pharm. Sci. 47 2012 265 272 10.1016/j.ejps.2012.04.009
23. G.P. Kumar, and P. Rajeshwarrao Nonionic surfactant vesicular systems for effective drug delivery - an overview APSB 1 2011 208 219
24. U.M. Le, D.S. Shaker, B.R. Sloat, and Z. Cui A thermo-sensitive polymeric gel containing a gadolinium (Gd) compound encapsulated into liposomes significantly extended the retention of the Gd in tumors Drug Dev. Ind. Pharm. 34 2008 413 418 10.1080/03639040701662495
25. S.C. Lee, K.E. Lee, J.J. Kim, and S.H. Lim The effectof cholesterol in the liposome bilayer on the stabilization of incorporated Retinol J. Liposome Res. 15 2005 157 166
26. Y. Li, H. He, X. Jia, W.L. Lu, J. Lou, and Y. Wei A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas Biomaterials 33 2012 3899 3908 10.1016/j.biomaterials.2012.02.004
27. M. Licciardi, G. Cavallaro, M. Di Stefano, G. Pitarresi, C. Fiorica, and G. Giammona Newself-assembling polyaspartylhydrazide copolymer micelles for anticancer drug delivery Int. J. Pharm. 396 2010 219 228 10.1016/j.ijpharm.2010.06.021
28. Z.N. Mahmoudi, S.B. Upadhye, D. Ferrizzi, and A.R. Rajabi-Siahboomi In vitro characterization of a novel polymeric system for preparation of amorphous solid drug dispersions AAPS J. 16 2014 685 697 10.1208/s12248-014-9590-y
29. D.S. Mali, B.K. Nanjwade, B.S. Unger, and F.V. Manvi In-vivo study of tissue distribution of tamoxifen loaded stealth liposomes in mammry tumor J. Cell Tissue Res. 13 2013 3451 3454
30. M.T. Marin, M.V. Margarit, and G.E. Salcedo Characterization and solubility study of solid dispersions of flunarizine and polyvinylpyrrolidone Farmaco 57 2002 723 727
31. S. Moghassemi, and A. Hadjizadeh Nano-niosomes as nanoscale drug delivery systems: an illustrated review J. Control. Release 185 2014 22 36 10.1016/j.jconrel.2014.04.015
32. A.J. Murray The genetics of breast cancer Surgery (Oxford) 28 2010 103 106
33. Y. Nakase, A. Hagiwara, S. Kin, K. Fukuda, T. Ito, T. Takagi, J. Fujiyama, C. Sakakura, E. Otsuji, and H. Yamagishi Intratumoral administration of methotrexate bound to activated carbon particles: antitumor effectiveness against human colon carcinoma xenografts and acute toxicity in mice J. Pharmacol. Exp. Ther. 311 2004 382 387
34. B. Nasseri Effect of cholesterol and temperature on the elastic properties of niosomal membranes Int. J. Pharm. 300 2005 95 101
35. D. Paolino, D. Cosco, R. Muzzalupo, E. Trapasso, N. Picci, and M. Fresta Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer Int. J. Pharm. 353 2008 233 242 10.1016/j.ijpharm.2007.11.037
36. B. Perillo, A. Sasso, C. Abbondanza, and G. Palumbo 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence Mol. Cell. Biol. 20 2000 2890 2901
37. J.A. Pillai, and J.H. Siegel Interaction of tamoxifen and noise-induceddamage to the cochlea Hear. Res. 282 2011 161 166 10.1016/j.heares.2011.08.012
38. J. Sancéau, Poupon, M.F. Delattre, O. Sastre-Garau, X. Wietzerbin, and J Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide Oncogene 21 2002 7700 7709
39. K.K. Sarwa, P.K. Suresh, M. Debnath, and M.Z. Ahmad Tamoxifen citrate loaded ethosomes for transdermal drug delivery system: preparation and characterization Curr. Drug Deliv. 10 2013 466 476
40. Z. Sezgin-Bayindir, A. Onay-Besikci, N. Vural, and N. Yuksel Niosomes encapsulating paclitaxel for oral bioavailability enhancement: preparation, characterization, pharmacokinetics and biodistribution J. Microencapsul. 30 2013 796 804 10.3109/02652048.2013.788088
41. D.S. Shaker, M.K. Ghorab, and M.S. Teiama Comparative studies on dissolution and bioavailability of tamoxifen citrate loaded binary and ternary solid dispersions BJPR 4 2014 215 229
42. D.S. Shaker, M. Nasr, and M. Mostafa Bioavailability and hypcholestrolemic effect of proniosomal simvastatin for transdermal delivery Int. J. Pharm. Pharm. Sci. 5 2013 344 351
43. L.A. Silva, K.A. Nascimento, M.C. Maciel, M.T. Pinheiro, P.R. Sousa, S.C. Ferreira, A.P. Azevedo, R.N. Guerra, and F.R. Nascimento Sunflower seed oil-enriched product can inhibit Ehrlich solid tumor growth in mice Chemotherapy 52 2006 91 94
44. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112
45. L. Tavano, M. Vivacqua, V. Carito, R. Muzzalupo, M.C. Caroleo, and F. Nicoletta Doxorubicin loaded magneto-niosomes for targeted drug delivery Colloids Surf. B Biointerfaces 102 2013 803 807 10.1016/j.colsurfb.2012.09.019
46. The British Pharmacopoeia, 2009. vol. III, pp. 10114.
47. I.F. Uchegbu, and R. Duncan Niosomes containing N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin (PK1): effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution Int. J. Pharm. 155 1997 7 17
48. T.J. Van De Voort, M.A. Felder, R.K.P.M. Yang Sondel, and A.L. Rakhmilevich Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice J. Immunother. 36 2013 29 40 10.1097/CJI.0b013e3182780f61
49. J. Xing, Qi, X. Jiang, Y. Zhu, X. Zhang, Z. Qin, X. Wu, and Z Topotecan hydrochloride liposomes incorporated into thermosensitive hydrogel for sustained and efficient in situ therapy of H22 tumor in Kunming mice Pharm. Dev. Technol. 2014 1 8 10.3109/10837450.2014.926918
50. G. Yang, S. Nowsheen, K. Aziz, and A.G. Georgakilas Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs Pharmacol. Ther. 139 2013 392 404 10.1016/j.pharmthera.2013.05.005
51. R.K. Yang, N.A. Kalogriopoulos, A.L. Rakhmilevich, E.A. Ranheim, S. Seo, K. Kim, K.L. Alderson, J. Gan, R.A. Reisfeld, S.D. Gillies, J.A. Hank, and P.M. Sondel Intratumoral hu14. 18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention J. Immunol. 189 2012 2656 2664 10.4049/jimmunol.1200934